[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]

MeSH terms

• Administration, Oral
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / pharmacology
• Antineoplastic Agents / therapeutic use*
• Benzenesulfonates / administration & dosage
• Benzenesulfonates / adverse effects
• Benzenesulfonates / pharmacology
• Benzenesulfonates / therapeutic use*
• Carcinoma, Hepatocellular / diagnostic imaging
• Carcinoma, Hepatocellular / drug therapy*
• Carcinoma, Hepatocellular / enzymology
• Carcinoma, Hepatocellular / nursing
• Cardiovascular Diseases / chemically induced
• Clinical Trials as Topic
• Drug Eruptions / drug therapy
• Drug Eruptions / etiology
• Drug Interactions
• Drug Monitoring
• Gastrointestinal Diseases / chemically induced
• Humans
• Liver Cirrhosis / complications
• Liver Cirrhosis / therapy
• Liver Neoplasms / diagnostic imaging
• Liver Neoplasms / drug therapy*
• Liver Neoplasms / enzymology
• Liver Neoplasms / nursing
• Molecular Targeted Therapy
• Neoplasm Proteins / antagonists & inhibitors
• Niacinamide / analogs & derivatives
• Patient Selection
• Phenylurea Compounds
• Practice Guidelines as Topic
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / pharmacology
• Protein Kinase Inhibitors / therapeutic use*
• Pyridines / administration & dosage
• Pyridines / adverse effects
• Pyridines / pharmacology
• Pyridines / therapeutic use*
• Radiography
• Sorafenib
• Spain
• raf Kinases / antagonists & inhibitors